Huntington National Bank continued to hold its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 76,325 shares of the company’s stock at the end of the second quarter. Huntington National Bank’s holdings in Teva Pharmaceutical Industries were worth $4,756,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. RNC Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 384.5% in the second quarter. RNC Capital Management LLC now owns 392,970 shares of the company’s stock valued at $19,739,000 after buying an additional 311,856 shares during the period. Panagora Asset Management Inc. boosted its stake in Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock valued at $37,590,000 after buying an additional 480,509 shares during the period. Trust Department MB Financial Bank N A boosted its stake in Teva Pharmaceutical Industries by 2.9% in the second quarter. Trust Department MB Financial Bank N A now owns 10,287 shares of the company’s stock valued at $608,000 after buying an additional 287 shares during the period. BLB&B Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 1.2% in the first quarter. BLB&B Advisors LLC now owns 25,978 shares of the company’s stock valued at $1,390,000 after buying an additional 302 shares during the period. Finally, Samlyn Capital LLC boosted its stake in Teva Pharmaceutical Industries by 18.5% in the first quarter. Samlyn Capital LLC now owns 1,954,175 shares of the company’s stock valued at $104,568,000 after buying an additional 305,662 shares during the period.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded down 0.67% during trading on Tuesday, hitting $50.36. The stock had a trading volume of 3,440,644 shares. The stock has a market cap of $46.03 billion, a price-to-earnings ratio of 33.64 and a beta of 0.82. Teva Pharmaceutical Industries Ltd has a one year low of $48.01 and a one year high of $66.55. The stock’s 50-day moving average price is $52.25 and its 200 day moving average price is $53.29.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.05. The firm had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.86 billion. During the same quarter last year, the company earned $1.43 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd will post $5.26 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Monday, August 22nd were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date was Thursday, August 18th.

TEVA has been the topic of a number of research analyst reports. Mizuho reiterated a “buy” rating and issued a $64.00 target price (down previously from $70.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, August 25th. Oppenheimer Holdings Inc. set a $66.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, September 12th. Leerink Swann set a $61.00 target price on Teva Pharmaceutical Industries and gave the company an “outperform” rating in a report on Wednesday, August 31st. Credit Suisse Group AG reiterated a “neutral” rating and issued a $51.63 target price (down previously from $59.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, August 25th. Finally, Vetr upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $60.02 target price on the stock in a report on Monday, August 1st. Seven analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $67.54.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.